ID	Database	Citation
22437870	Pubmed	"The blockade of immune checkpoints in cancer immunotherapy. Pardoll DM. Nat Rev Cancer. 2012 Mar 22;12(4):252–64.  <a href=""http://www.ncbi.nlm.nih.gov/pubmed/22437870"" target=""_blank"" class=""external"" rel=""nofollow"">PubMed</a> <a href=""https://europepmc.org/abstract/MED/22437870"" target=""_blank"" class=""external"" rel=""nofollow"">Europe PMC</a> <a href=""https://scholia.toolforge.org/pubmed/22437870"" target=""_blank"" class=""external"" rel=""nofollow"">Scholia</a>"
25514926	Pubmed	"PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. Hornbeck PV, Zhang B, Murray B, Kornhauser JM, Latham V, Skrzypek E. Nucleic Acids Res. 2015 Jan;43(Database issue):D512-20.  <a href=""http://www.ncbi.nlm.nih.gov/pubmed/25514926"" target=""_blank"" class=""external"" rel=""nofollow"">PubMed</a> <a href=""https://europepmc.org/abstract/MED/25514926"" target=""_blank"" class=""external"" rel=""nofollow"">Europe PMC</a> <a href=""https://scholia.toolforge.org/pubmed/25514926"" target=""_blank"" class=""external"" rel=""nofollow"">Scholia</a>"
28643244	Pubmed	"Durvalumab: First Global Approval. Syed YY. Drugs. 2017 Aug;77(12):1369–76.  <a href=""http://www.ncbi.nlm.nih.gov/pubmed/28643244"" target=""_blank"" class=""external"" rel=""nofollow"">PubMed</a> <a href=""https://europepmc.org/abstract/MED/28643244"" target=""_blank"" class=""external"" rel=""nofollow"">Europe PMC</a> <a href=""https://scholia.toolforge.org/pubmed/28643244"" target=""_blank"" class=""external"" rel=""nofollow"">Scholia</a>"
28990585	Pubmed	"The diverse functions of the PD1 inhibitory pathway. Sharpe AH, Pauken KE. Nat Rev Immunol. 2018 Mar;18(3):153–67.  <a href=""http://www.ncbi.nlm.nih.gov/pubmed/28990585"" target=""_blank"" class=""external"" rel=""nofollow"">PubMed</a> <a href=""https://europepmc.org/abstract/MED/28990585"" target=""_blank"" class=""external"" rel=""nofollow"">Europe PMC</a> <a href=""https://scholia.toolforge.org/pubmed/28990585"" target=""_blank"" class=""external"" rel=""nofollow"">Scholia</a>"
29347993	Pubmed	"Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. Kaufman HL, Russell JS, Hamid O, Bhatia S, Terheyden P, D’Angelo SP, et al. J Immunother Cancer. 2018 Jan 19;6(1):7.  <a href=""http://www.ncbi.nlm.nih.gov/pubmed/29347993"" target=""_blank"" class=""external"" rel=""nofollow"">PubMed</a> <a href=""https://europepmc.org/abstract/MED/29347993"" target=""_blank"" class=""external"" rel=""nofollow"">Europe PMC</a> <a href=""https://scholia.toolforge.org/pubmed/29347993"" target=""_blank"" class=""external"" rel=""nofollow"">Scholia</a>"
30345906	Pubmed	"Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. N Engl J Med. 2018 Nov 29;379(22):2108–21.  <a href=""http://www.ncbi.nlm.nih.gov/pubmed/30345906"" target=""_blank"" class=""external"" rel=""nofollow"">PubMed</a> <a href=""https://europepmc.org/abstract/MED/30345906"" target=""_blank"" class=""external"" rel=""nofollow"">Europe PMC</a> <a href=""https://scholia.toolforge.org/pubmed/30345906"" target=""_blank"" class=""external"" rel=""nofollow"">Scholia</a>"
30511409	Pubmed	"Immune checkpoint blockade opens a new way to cancer immunotherapy. Sadreddini S, Baradaran B, Aghebati-Maleki A, Sadreddini S, Shanehbandi D, Fotouhi A, et al. J Cell Physiol. 2019 Jun;234(6):8541–9.  <a href=""http://www.ncbi.nlm.nih.gov/pubmed/30511409"" target=""_blank"" class=""external"" rel=""nofollow"">PubMed</a> <a href=""https://europepmc.org/abstract/MED/30511409"" target=""_blank"" class=""external"" rel=""nofollow"">Europe PMC</a> <a href=""https://scholia.toolforge.org/pubmed/30511409"" target=""_blank"" class=""external"" rel=""nofollow"">Scholia</a>"